These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 25436736

  • 21. Not all women diagnosed with PCOS share the same cardiovascular risk profiles.
    Jovanovic VP, Carmina E, Lobo RA.
    Fertil Steril; 2010 Aug; 94(3):826-32. PubMed ID: 19501355
    [Abstract] [Full Text] [Related]

  • 22. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A, Patton L, De Iasio R, Palladoro F, Pagotto U, Pasquali R.
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [Abstract] [Full Text] [Related]

  • 23. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
    Sanchez-Garrido MA, Tena-Sempere M.
    Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
    [Abstract] [Full Text] [Related]

  • 24. The impact of obesity on reproduction in women with polycystic ovary syndrome.
    Pasquali R, Gambineri A, Pagotto U.
    BJOG; 2006 Oct; 113(10):1148-59. PubMed ID: 16827825
    [Abstract] [Full Text] [Related]

  • 25. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk?
    Daan NM, Louwers YV, Koster MP, Eijkemans MJ, de Rijke YB, Lentjes EW, Fauser BC, Laven JS.
    Fertil Steril; 2014 Nov; 102(5):1444-1451.e3. PubMed ID: 25239303
    [Abstract] [Full Text] [Related]

  • 26. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives.
    Cussons AJ, Stuckey BG, Watts GF.
    Atherosclerosis; 2006 Apr; 185(2):227-39. PubMed ID: 16313910
    [Abstract] [Full Text] [Related]

  • 27. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
    Caldwell AS, Middleton LJ, Jimenez M, Desai R, McMahon AC, Allan CM, Handelsman DJ, Walters KA.
    Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
    [Abstract] [Full Text] [Related]

  • 28. Discovery of Novel Lipid Profiles in PCOS: Do Insulin and Androgen Oppositely Regulate Bioactive Lipid Production?
    Li S, Chu Q, Ma J, Sun Y, Tao T, Huang R, Liao Y, Yue J, Zheng J, Wang L, Xue X, Zhu M, Kang X, Yin H, Liu W.
    J Clin Endocrinol Metab; 2017 Mar 01; 102(3):810-821. PubMed ID: 27886515
    [Abstract] [Full Text] [Related]

  • 29. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.
    Azziz R.
    J Clin Endocrinol Metab; 2006 Mar 01; 91(3):781-5. PubMed ID: 16418211
    [Abstract] [Full Text] [Related]

  • 30. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters.
    Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA.
    J Clin Endocrinol Metab; 2005 May 01; 90(5):2545-9. PubMed ID: 15728203
    [Abstract] [Full Text] [Related]

  • 31. Cardiometabolic and reproductive benefits of early dietary energy restriction and voluntary exercise in an obese PCOS-prone rodent model.
    Diane A, Kupreeva M, Borthwick F, Proctor SD, Pierce WD, Vine DF.
    J Endocrinol; 2015 Sep 01; 226(3):193-206. PubMed ID: 26187902
    [Abstract] [Full Text] [Related]

  • 32. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome.
    Diamanti-Kandarakis E, Kandaraki E, Christakou C, Panidis D.
    Obes Rev; 2009 Jul 01; 10(4):431-41. PubMed ID: 19413702
    [Abstract] [Full Text] [Related]

  • 33. Hepatic manifestations of women with polycystic ovary syndrome.
    Chen MJ, Ho HN.
    Best Pract Res Clin Obstet Gynaecol; 2016 Nov 01; 37():119-128. PubMed ID: 27107966
    [Abstract] [Full Text] [Related]

  • 34. A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome.
    Shi D, Dyck MK, Uwiera RR, Russell JC, Proctor SD, Vine DF.
    Endocrinology; 2009 Sep 01; 150(9):4425-36. PubMed ID: 19470707
    [Abstract] [Full Text] [Related]

  • 35. Telomere Length Differently Associated to Obesity and Hyperandrogenism in Women With Polycystic Ovary Syndrome.
    Velazquez ME, Millan AL, Rojo M, Abruzzese GA, Cocucci SE, Iglesias Molli AE, Frechtel GD, Motta AB, Cerrone GE.
    Front Endocrinol (Lausanne); 2021 Sep 01; 12():604215. PubMed ID: 34054718
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance.
    Ketel IJ, Stehouwer CD, Serné EH, Korsen TJ, Hompes PG, Smulders YM, de Jongh RT, Homburg R, Lambalk CB.
    J Clin Endocrinol Metab; 2008 Sep 01; 93(9):3365-72. PubMed ID: 18593766
    [Abstract] [Full Text] [Related]

  • 39. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors.
    Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC.
    BJOG; 2006 Oct 01; 113(10):1210-7. PubMed ID: 16972863
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.